目的 探討結(jié)核丸聯(lián)合環(huán)絲氨酸治療耐藥性肺結(jié)核的臨床效果以及對(duì)患者炎性因子水平的影響。方法 將西安市胸科醫(yī)院自2015年1月-2017年12月確診的耐藥性肺結(jié)核患者106例作為研究對(duì)象，按隨機(jī)法分為觀察組和對(duì)照組各53例，觀察組使用結(jié)核丸聯(lián)合環(huán)絲氨酸進(jìn)行治療，對(duì)照組僅使用環(huán)絲氨酸進(jìn)行治療，對(duì)比觀察兩組患者的臨床療效和體內(nèi)炎性因子水平的變化情況。結(jié)果 治療后兩組患者痰細(xì)菌學(xué)轉(zhuǎn)陰率分別為66.04%和62.26%，組間比較差異無統(tǒng)計(jì)學(xué)意義。治療后觀察組患者病灶吸收有效率為86.79%，明顯高于對(duì)照組的73.58%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組患者干擾素-γ（INF-γ）水平明顯升高，白介素-4（IL-4）、C反應(yīng)蛋白（CRP）和腫瘤壞死因子-α（TNF-α）水平均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；其中觀察組患者改善程度明顯優(yōu)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 使用結(jié)核丸聯(lián)合環(huán)絲氨酸治療耐藥性肺結(jié)核患者可有效提高患者治療效果，降低機(jī)體內(nèi)炎性反應(yīng)，可推廣使用。

Objective To investigate the clinical effect of tuberculous pill combined with cycloserine in the treatment of drugresistant pneumonia and its influence on the level of inflammatory factors. Methods 106 cases of drug-resistant pulmonary tuberculosis confirmed in our hospital from January 2015 to December 2017 were divided into study group and 53 cases in control group. The study group was treated with tuberculosis pill combined with cycloserine. The control group was treated with only cycloserine, and the clinical efficacy of the two groups was compared. And the changes in the levels of inflammatory factors in the body. Results after treatment, the negative rate of phlegm bacteriology was 66.04% and 62.26%, respectively, and there was no significant difference between the two groups. The effective rate of focus absorption was 86.79% after treatment, which was significantly higher than that in the control group 73.58% (P<0.05), and the level of INF-gamma in the two groups after treatment was obvious. The levels of IL-4, CRP and TNF-alpha were significantly decreased, and the improvement of the patients in the study group was significantly better than that of the control group (P<0.05). Conclusion The use of tuberculosis pills and cycserine in the treatment of drug-resistant pulmonary tuberculosis can effectively improve the therapeutic effect of the patients and reduce the inflammatory reaction in the body. It is a safe and effective Chinese patent medicine, which can be popularized.

R978.3